Spozhmy Panezai, MD
Neurology · Edison, NJNPI 1457378945
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Medtronic at 33.7% of the total. Reporting peaked in 2022 at $90 and has fallen 84.5% since, to $14 in 2025. That places this record below the midpoint for neurology clinicians in NJ, where the typical reported total is $1,560.
Across 10 payments — averaging $21.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$73
- Johnson & Johnson$45
- Stryker$37
- SK Life Science, Inc.$17
- Janssen Scientific Affairs, LLC$15
- AstraZeneca$15
- plus $14 from 1 others
Across 1 payment — averaging $23,990 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$24K
What the payments were for
- Food & beverage$215100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 2 | $73 |
| Johnson & Johnson | 2 | $45 |
| Stryker | 2 | $37 |
| SK Life Science, Inc. | 1 | $17 |
| Janssen Scientific Affairs, LLC | 1 | $15 |
| AstraZeneca | 1 | $15 |
| AbbVie | 1 | $14 |
How this compares
$215 in reported general payments places this provider in the 20th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 16 | $14,503 |
| Atorvastatin Calcium | 44 | $341 |
| Quetiapine Fumarate | 12 | $70 |
| Amlodipine Besylate | 11 | $45 |
Paid to pharmacies, not to this prescriber.
Other neurology in Edison
- Marina SobolEdison$69K
- Igor SobolEdison$55K
- Wei Wei MaEdison$39K
- Steven BromleyAudubon$1.5M
- Mary Ann PiconeTeaneck$1.5M
- Fiona GuptaOradell$1.1M
- Matthew DavisMiddletown$567K
- Amos KatzEatontown$558K
- Monte PellmarFreehold$429K
- Marcie RabinSummit$387K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.